Abstract
Because of its ability to efficiently inhibit in vitro cytokine production by activated macrophages, we hypothesized that interleukin (IL) 10 might be of particular interest in preventing endotoxin-induced toxicity. We therefore examined the effects of IL-10 administration before lipopolysaccharide (LPS) challenge in mice. A marked reduction in the amounts of LPS-induced tumor necrosis factor (TNF) release in the circulation was observed after IL-10 pretreatment at doses at low as 10 U. IL-10 also efficiently prevented the hypothermia generated by the injection of 100 micrograms LPS. Finally, pretreatment with a single injection of 1,000 U IL-10 completely prevented the mortality consecutive to the challenge with 500 micrograms LPS, a dose that was lethal in 50% of the control mice. We conclude that IL-10 inhibits in vivo TNF secretion and protects against the lethality of endotoxin in a murine model of septic shock.
MeSH Terms
Animals
Base Sequence
Endotoxins/toxicity
Hypothermia/prevention & control
Interleukin-10/pharmacology
Lipopolysaccharides/toxicity
Mice
Mice, Inbred BALB C
Molecular Sequence Data
Oligodeoxyribonucleotides/chemistry
Secretory Rate/drug effects
Shock, Septic/prevention & control
Tumor Necrosis Factor-alpha/metabolism
Chemicals
Endotoxins
Lipopolysaccharides
Oligodeoxyribonucleotides
Tumor Necrosis Factor-alpha
Interleukin-10
Authors & Affiliations
9 authors, click to expand affiliations / ORCID
Gérard C
Institut de Recherche Interdisciplinaire, Université Libre de Bruxelles, Belgium.
Bruyns C
Marchant A
Abramowicz D
Vandenabeele P
Delvaux A
Fiers W
Goldman M
Velu T
References (24)
24 references, click to expand
-
IL-10 inhibits cytokine production by activated macrophages.
J Immunol. 1991 Dec 1;147(11):3815-22
PMID: 1940369
-
Septic shock: pathogenesis.
Lancet. 1991 Sep 21;338(8769):732-6
PMID: 1679876
-
Macrophage deactivation by interleukin 10.
J Exp Med. 1991 Dec 1;174(6):1549-55
PMID: 1744584
-
Differentiation factor/leukemia inhibitory factor protection against lethal endotoxemia in mice: synergistic effect with interleukin 1 and tumor necrosis factor.
J Exp Med. 1992 Apr 1;175(4):1139-42
PMID: 1552284
-
Granulocyte colony-stimulating factor treatment protects rodents against lipopolysaccharide-induced toxicity via suppression of systemic tumor necrosis factor-alpha.
J Immunol. 1992 Aug 1;149(3):918-24
PMID: 1378868
-
Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin.
Science. 1985 Aug 30;229(4716):869-71
PMID: 3895437
-
The use of thin acrylamide gels for DNA sequencing.
FEBS Lett. 1978 Mar 1;87(1):107-10
PMID: 631324
-
Identification of a monoclonal antibody specific for a murine T3 polypeptide.
Proc Natl Acad Sci U S A. 1987 Mar;84(5):1374-8
PMID: 2950524
-
Tumor necrosis factor mediates endotoxic effects in mice.
Infect Immun. 1987 Jul;55(7):1622-5
PMID: 3596805
-
Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia.
Nature. 1987 Dec 17-23;330(6149):662-4
PMID: 3317066
-
Epidermal-growth-factor-dependent transformation by a human EGF receptor proto-oncogene.
Science. 1987 Dec 4;238(4832):1408-10
PMID: 3500513
-
Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition.
J Clin Invest. 1988 Apr;81(4):1162-72
PMID: 3258319
-
Structure-function relationship of tumour necrosis factor and its mechanism of action.
Ciba Found Symp. 1987;131:109-23
PMID: 3131072
-
Participation of tumor necrosis factor in the mediation of gram negative bacterial lipopolysaccharide-induced injury in rabbits.
J Clin Invest. 1988 Jun;81(6):1925-37
PMID: 3384955
-
Retroviruses expressing different levels of the normal epidermal growth factor receptor: biological properties and new bioassay.
J Cell Biochem. 1989 Feb;39(2):153-66
PMID: 2565908
-
A role for interleukin 1 in the in vivo actions of tumor necrosis factor.
Lymphokine Res. 1989 Fall;8(3):269-74
PMID: 2789321
-
Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BCRFI.
Science. 1990 Jun 8;248(4960):1230-4
PMID: 2161559
-
Prophylactic and therapeutic effects of a monoclonal antibody to tumor necrosis factor-alpha in experimental gram-negative shock.
J Infect Dis. 1990 Aug;162(2):421-7
PMID: 2373872
-
Isolation of monoclonal antibodies specific for IL-4, IL-5, IL-6, and a new Th2-specific cytokine (IL-10), cytokine synthesis inhibitory factor, by using a solid phase radioimmunoadsorbent assay.
J Immunol. 1990 Nov 1;145(9):2938-45
PMID: 2145365
-
Interleukin-1 receptor antagonist reduces mortality from endotoxin shock.
Nature. 1990 Dec 6;348(6301):550-2
PMID: 2147233
-
A specific receptor antagonist for interleukin 1 prevents Escherichia coli-induced shock in rabbits.
FASEB J. 1991 Mar 1;5(3):338-43
PMID: 1825816
-
A recombinant human receptor antagonist to interleukin 1 improves survival after lethal endotoxemia in mice.
J Exp Med. 1991 Apr 1;173(4):1029-32
PMID: 1826127
-
Inhibition of interleukin 1 (IL-1) binding and bioactivity in vitro and modulation of acute inflammation in vivo by IL-1 receptor antagonist and anti-IL-1 receptor monoclonal antibody.
J Exp Med. 1991 Apr 1;173(4):931-9
PMID: 1826128
-
Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes.
J Exp Med. 1991 Nov 1;174(5):1209-20
PMID: 1940799